Article Contents ::
- 1 Details About Generic Salt :: Cefuroxi
- 2 Main Medicine Class:: Antibiotic,cephalosporin
- 3 (SEFF-yur-OX-eem) Ceftin, Kefurox, Zinacef Class: Antibiotic/cephalosporin
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Cefuroxi
Main Medicine Class:: Antibiotic,cephalosporin
Ceftin, Kefurox, Zinacef
Drugs Class ::
Action Inhibits mucopeptide synthesis in bacterial cell wall.
Indications for Drugs ::
Indications Oral form: Treatment of infections of lower respiratory tract, urinary tract, skin and skin structures; treatment of uncomplicated gonorrhea, otitis media, pharyngitis and tonsillitis due to susceptible strains of specific micro-organisms. Treatment of early Lyme disease, pharyngitis/tonsillitis and impetigo. Parenteral form: Treatment of infections of lower respiratory tract, urinary tract, skin and skin structures, bone and joint; preoperative prophylaxis; treatment of septicemia, gonorrhea and meningitis due to susceptible strains of specific microorganisms.
Drug Dose ::
ADULTS & CHILDREN ³ 12 YR: PO 125–500 mg bid. IV/IM 750 mg-1.5 g q 8 hr. CHILDREN < 12 YR: PO 125–250 mg bid. Infants & CHILDREN (> 3 MO): IV/IM 50–150 mg/kg/day (not to exceed adult dose) in equally divided doses q 6–8 hr.
ADULTS & CHILDREN ³ 12 YR: IV/IM Up to 3 g q 8 hr. INFANTS & CHILDREN 3 MO-12 YR: IV/IM 200–240 mg/kg/day in divided doses q 6–8 hr.
ADULTS & CHILDREN ³ 12 YR: PO 1 g as single dose. IM 1.5 g as single dose.
ADULTS: IV/IM 1.5 g ½–1 hr before surgery then 750 mg q 8 hr for duration of surgery.
Contraindications Hypersensitivity to cephalosporins.
Drug Precautions ::
Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy in children < 3 mo not established. Hypersensitivity: Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients due to possible cross-reactivity. Pseudomembranous colitis: Should be considered in patients in whom diarrhea develops. Renal impairment: Use drug with caution in patients with renal impairment. Dosage adjustment based on renal function may be required. Superinfection: May result in bacterial or fungal overgrowth of non-susceptible microorganisms.
PATIENT CARE CONSIDERATIONS
Drug Side Effects ::
GI: Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis. GU: Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy. HEMA: Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage. HEPA: Hepatic dysfunction; abnormal liver function test results. OTHER: Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness-like reactions (eg, skin rashes, polyarthritis, arthralgia, fever); phlebitis, thrombophlebitis and pain at injection site.
Drug Mode of Action ::
Action Inhibits mucopeptide synthesis in bacterial cell wall.
Drug Interactions ::
Aminoglycosides: Increased risk of nephrotoxicity with parenteral cefuroxime. Probenecid: Inhibition of renal excretion of cefuroxime. INCOMPATIBILITIES: Aminoglycosides: Do not add aminoglycosides to cefuroxime solutions because inactivation of both drugs may result; administer at separate sites if concurrent therapy is indicated.
Drug Assesment ::
- Obtain patient history, including drug history and any known allergies. Note renal impairment and allergy to cephalosporins or penicillins.
- Obtain specimens for culture and sensitivity before beginning therapy and periodically during treatment.
- Monitor renal function carefully during treatment.
- Monitor for signs of infection, especially fever, and for positive response to antibiotic therapy.
- Assess for signs and symptoms of anaphylaxis (shortness of breath, wheezing, laryngeal spasm). Have resuscitation equipment available.
- Assess for signs of superinfection, such as vaginitis or stomatitis.
- Assess for diarrhea with blood or pus, which may be symptom of pseudomembranous colitis. Symptoms may occur after antibiotic treatment.
- Monitor IV site for infiltration, infection and thrombophlebitis.
Drug Storage/Management ::
- Sodium salt is for parenteral administration. Axetil salt is for oral administration.
- Administer oral form with food to enhance absorption.
- May crush and mix with food or beverages; however, crushed tablets have strong, persistent bitter taste. Consider alternative therapy if children cannot swallow whole tablets.
- Reconstituted solution should be light yellow to amber. Do not administer if solution is cloudy or precipitate is present.
- When giving by IM route, shake IM suspension gently before administration. Aspirate to prevent injection into blood vessel. Inject deeply into large muscle (eg, upper outer quadrant of gluteus muscle or lateral thigh); massage well. Rotate injection sites.
- When giving by IV route, use direct intermittent infusion. Administer slowly over 3–5 min. Change IV sites q 48–72 hr.
- For intermittent IV infusion with Y-type administration set, administer over 30 min. and temporarily stop other solutions at Y-site.
- For continuous infusion, reconstituted solution may be further diluted with D5W or 0.9% Sodium Chloride.
- Reconstituted solution is stable for 24 hr at room temperature. When refrigerated, solution in vials is stable for 48 hr; IV solution is stable for 7 days when refrigerated.
- Completely thaw frozen solution at room temperature before use; do not refreeze.
- Do not add supplementary medication to premixed solution.
- Store sterile powder at room temperature and protect from light.
- Store tablets at room temperature.
Drug Notes ::
- Instruct patient to complete full course of therapy.
- Advise patient to take with meals to enhance absorption. If tablet must be crushed, mix with food or beverage.
- Advise parent to contact physician if child is unable to tolerate crushed tablet with food or beverage.
- Remind patient to check body temperature daily. If fever persists for more than a few days or if high fever (> 102°F) or shaking chills are noted, physician should be notified immediately.
- Advise patient to maintain normal fluid intake while using this medication.
- Advise diabetic patient to use enzyme-based tests (eg, Clinistix, Testape) for monitoring urine glucose because drug may give false results with other tests.
- Instruct patient to report these symptoms to physician: nausea, vomiting, diarrhea, skin rash, sore throat, bruising, hives, muscle or joint pain.
- Instruct patient to report signs of superinfection: black “furry” tongue, white patches in mouth, foul-smelling stools, vaginal itching or discharge.
- Warn patient that diarrhea that contains blood or pus may be a sign of serious disorders. Tell patient to seek medical care and not to treat at home.
- Instruct patient to seek emergency care immediately if wheezing or difficulty breathing occurs.